Roth Capital resumed coverage of LeMaitre (LMAT) with a Buy rating and $108 price target The firm says the company’s product portfolio vascular surgeons combined with its direct sales force of 164 reps is driving organic sales growth of 15% with favorable operating leverage. It sees upcoming catalysts for LeMaitre from RestoreFlow approvals in Ireland and Germany as well as the XenoSure vascular patch regulatory submission in China.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMAT: